Search International and National Patent Collections

1. (WO2018001874) FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE

Pub. No.:    WO/2018/001874    International Application No.:    PCT/EP2017/065472
Publication Date: Fri Jan 05 00:59:59 CET 2018 International Filing Date: Fri Jun 23 01:59:59 CEST 2017
IPC: C07K 14/725
C12N 5/0783
A61K 39/00
Applicants: MEDIZINISCHE HOCHSCHULE HANNOVER
TECHNISCHE UNIVERSITÄT BRAUNSCHWEIG
Inventors: JÄCKEL, Dr. Elmar
NOYAN, Dr. Fatih
HUST, Prof. Dr. Michael
Title: FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE
Abstract:
The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host´s immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02or SLA-01*0401in a recipient patient who is negative for HLA-A*02or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02or SLA-01*0401.